Impact of Virtual Reality on the Quality of Life of Oncology Patients

Launched by CENTRAL HOSPITAL SAINT QUENTIN · Jun 26, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how virtual reality (VR) can help improve the quality of life for cancer patients, particularly those experiencing anxiety, nausea, and vomiting during their first chemotherapy treatments. The researchers believe that using immersive VR may help reduce these unpleasant symptoms and make the overall experience of treatment more manageable. They will also look at how satisfied both the patients and nursing staff are with this approach.

To be eligible for this trial, participants should be starting their first round of intravenous chemotherapy and must not have undergone chemotherapy before. They need to understand either French or English, and the chemotherapy session should last longer than 30 minutes. However, there are some exclusions, such as patients with severe communication issues, certain medical conditions, or those who experience significant motion sickness. If you decide to participate, you'll receive full information about the study and will be asked to provide written consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chemotherapy-naive patient
• • Patient with first-line indication for intravenous cyclic chemotherapy
• • Affiliated to a social security system
• • Having received full information on the organization of the research and having given free, informed and written consent signed by the participant and the investigator
• • Patient understands French or English
• • Expected duration of chemotherapy session for the first 3 cycles greater than 30 minutes
• exclusion criteria :
• • Patient with communication disorders preventing informed consent
• • Patient under legal protection (guardianship, curatorship, safeguard of justice)
• • Patients suffering from epilepsy
• • Severe visual or hearing impairment preventing use of headphones
• • Psychiatric pathologies such as delusional disorders, hallucinations or schizophrenia.
• • Patients with infections or facial wounds
• • Patients with severe claustrophobia
• • Patients with pacemakers
• • Patients with known cognitive or learning problems,
• • Patients with brain tumors or metastases,
• • Patients suffering from motion sickness
• • Expected duration of chemotherapy session for the first 3 cycles of 30 minutes or less.